Article | OCT 29, 2025
This study evaluated over 750 echocardiograms from patients with transthyretin cardiac amyloidosis (ATTR-CM) using the Us2.ai software to track structural and functional heart changes over time. The results demonstrate that AI-driven echocardiographic analysis can effectively monitor disease progression and may support earlier detection of therapeutic response, offering a scalable and objective approach to managing patients with ATTR-CM.
Venneri, L., Aimo, A., Porcari, A., Sezer, I., Ioannou, A., Sheikh, A., Mansell, J., Razvi, Y., Iyer, S. B., Martinez‐Naharro, A., Bandera, F., Lim, S. C., Frost, M., Ezekowitz, J., Lam, C. S. P., Moody, W., Whelan, C., Lachmann, H., Ashutosh Wechelakar, & Emdin, M. (2025). Artificial intelligence‐based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.70073